Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q1 2016 · 10-Q
Revenue$59.37M$59.37M+4.4% vs Q1 2015 Net Income$2.49M$2.49MN/M vs Q1 2015 EPS Diluted$0.05$0.05N/M vs Q1 2015 Gross Profit$24,902,000+87.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flow$13,930,000+941.1% Free Cash Flowderived$9,984,000N/M Margins · derivedGross margin41.9%+18.6 pt vs Q1 2015
Operating margin6.9%+19.6 pt vs Q1 2015
Net margin4.2%+5.4 pt vs Q1 2015
ended Mar 31, 2016 · filed May 10, 2016 · 40 d after period end